Sphera Funds Management LTD. grew its position in Epizyme Inc (NASDAQ:EPZM) by 30.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 399,502 shares of the biopharmaceutical company’s stock after acquiring an additional 92,348 shares during the quarter. Sphera Funds Management LTD. owned about 0.50% of Epizyme worth $4,235,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Principal Financial Group Inc. purchased a new stake in shares of Epizyme in the first quarter valued at $187,000. BB&T Securities LLC raised its stake in shares of Epizyme by 45.5% in the second quarter. BB&T Securities LLC now owns 16,000 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 5,000 shares during the period. Shell Asset Management Co. purchased a new stake in shares of Epizyme in the third quarter valued at $198,000. BlueMountain Capital Management LLC purchased a new stake in shares of Epizyme in the second quarter valued at $320,000. Finally, Trexquant Investment LP purchased a new stake in shares of Epizyme in the second quarter valued at $328,000. 73.27% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have recently weighed in on EPZM shares. SunTrust Banks increased their target price on shares of Epizyme to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 25th. Cowen reissued a “buy” rating on shares of Epizyme in a research note on Monday, September 24th. Roth Capital set a $18.00 target price on shares of Epizyme and gave the company a “buy” rating in a research note on Monday, October 22nd. Oppenheimer set a $27.00 target price on shares of Epizyme and gave the company a “buy” rating in a research note on Friday, November 2nd. Finally, Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $8.25 target price on the stock in a research note on Monday, November 26th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $19.83.
In related news, Director David M. Mott purchased 416,667 shares of Epizyme stock in a transaction that occurred on Friday, October 5th. The shares were bought at an average price of $9.00 per share, with a total value of $3,750,003.00. Following the purchase, the director now directly owns 12,088 shares of the company’s stock, valued at approximately $108,792. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 21.50% of the company’s stock.
EPZM stock opened at $6.45 on Friday. The stock has a market capitalization of $528.05 million, a P/E ratio of -2.96 and a beta of 2.08. Epizyme Inc has a 12 month low of $6.42 and a 12 month high of $21.40.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Friday, November 2nd. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.07. As a group, analysts forecast that Epizyme Inc will post -1.93 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Epizyme Inc (EPZM) Stake Raised by Sphera Funds Management LTD.” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/12/08/epizyme-inc-epzm-stake-raised-by-sphera-funds-management-ltd.html.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
See Also: Risk Tolerance
Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme Inc (NASDAQ:EPZM).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.